FDA Approved: SAPHRIS — Supplemental Application (Allergan, Inc.)

View source ↗

Summary

FDA approved a supplemental application for SAPHRIS (asenapine) filed by Allergan, Inc., indicating an update to the product's labeling/indication.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Schizophrenia

Drugs mentioned

• Saphris (asenapine)

Snippet

SUPPL AP for SAPHRIS (ASENAPINE MALEATE)